Reflections on Plozasiran Trial Data and Future Potential
October 7th 2024Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.
Read More
SHASTA-2 Trial: Plozasiran’s Efficacy in Reducing Triglycerides and APOC3
October 7th 2024Panelists discuss how the SHASTA-2 study evaluated the efficacy and safety of plozasiran in reducing triglyceride levels and APOC3 in familial chylomicronemia syndrome, comparing outcomes with the placebo group and assessing implications for treating severe hypertriglyceridemia and preventing pancreatitis.
Read More
PALISADE Study: Plozasiran’s Efficacy and Potential in Reducing Triglycerides and Pancreatitis
September 30th 2024Panelists discuss how a multidisciplinary approach enhances the management of familial chylomicronemia syndrome by fostering collaboration among clinicians to address unmet treatment needs and optimize patient outcomes, while also exploring existing treatment gaps that contribute to ongoing risks of acute pancreatitis and hospitalization.
Read More
Emerging Research of RNAi-Based Therapies for FCS
September 30th 2024Panelists discuss how early diagnosis and intervention in familial chylomicronemia syndrome (FCS) are crucial for preventing cardiovascular and metabolic complications, emphasizing the key role clinicians play in initiating timely and effective treatment strategies.
Read More
Familial Chylomicronemia Syndrome: Diagnosis, Genetic Factors, and Long-Term Health Implications
September 23rd 2024Panelists discuss how familial chylomicronemia syndrome (FCS) is characterized by severe hypertriglyceridemia and genetic mutations in the LPL gene, highlighting the key diagnostic criteria and complications, such as acute pancreatitis, while emphasizing the impact of untreated FCS on patient quality of life and long-term health risks.
Read More
Quality of Life and Diagnostic Considerations for FCS
September 23rd 2024Panelists discuss how familial chylomicronemia syndrome (FCS) imposes a significant economic burden on patients, affecting their ability to stay employed and manage the costs associated with long-term care and treatment.
Read More